A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Artios Pharma Ltd
Esperas Pharma Inc.
AstraZeneca
University of Maryland, Baltimore
Altor BioScience